(PR NEWSWIRE) Antex Biologics Receives Patent for Helicobacter Pylori Vaccine
Antex Biologics Receives Patent for Helicobacter Pylori Vaccine
GAITHERSBURG, Md., April 26 /PRNewswire/ -- Antex Biologics today
announced that its Helicobacter ("H.") pylori vaccine, HELIVAX(TM), received
US Patent No. 6,051,416, entitled "Methods for Producing Enhanced Antigenic
Helicobacter Species." The vaccine is in clinical development and is produced
using the Company's proprietary NST(TM) (Nutriment Signal Transduction)
technology.
"We are pleased that the patent for this vaccine has issued. HELIVAX has
successfully completed a Phase I clinical trial. The clinical results from
human volunteers confirmed our preclinical findings in animals, that Antex's
orally administered HELIVAX is well tolerated and generates immune responses
systemically as well as mucosally, particularly at the site of Helicobacter
infections," said Dr. Larry Ellingsworth, Vice President, Research and
Development, at Antex.
"Our trial was the first demonstration in humans that a whole cell vaccine
against H. pylori is capable of generating these kinds of immunological
responses. Such responses may be important in fighting Helicobacter infections
in humans," continued Dr. Ellingsworth.
Results from the Phase I clinical trial were presented at the Third Annual
Winter H. pylori Workshop in February, 1999 and at The Second Conference of
Vaccine Research in March, 1999.
Dr. Esposito, Chairman and CEO of Antex, stated, "From our recent private
placement, we now have the funding to continue the clinical development of
this vaccine. Additional clinical studies will include establishing the
appropriate dosing regimen, evaluating other formulations and initial
effectiveness trials." |
